Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Hemophilia A Without Inhibitors: Personalizing Therapy With Factor VIII Prophylaxis: Webcast
  • CME
  • CE

Credits Available
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: December 8, 2020 Expiration: December 7, 2021
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Takeda Pharmaceuticals USA, LLC
Michael Callaghan, MD
Miguel A. Escobar, MD
Guy A. Young, MD

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the available safety and efficacy data on PK monitoring for patients with hemophilia A who are prescribed factor VIII products and the impact on dose, bleeding event rate, and clinical outcomes
  • Assess use of population PK and comparative PK to tailor hemophilia prophylaxis when switching factor products
  • Develop individualized prophylaxis management plans for special populations with hemophilia A without inhibitors
  • Educate the multidisciplinary team about available resources for estimating individual PK using a population PK approach
  • Personalize FVIII prophylactic therapy and counsel patients on strategies to optimally mitigate arthropathy and bone density loss in patients with hemophilia A without inhibitors

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Michael Callaghan, MD

Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Children's Hospital of Michigan
Detroit, Michigan

Michael Callaghan, MD, has disclosed that he has received consulting fees from Bayer, Biomarin, Catalyst, Global Blood Therapeutics, Hema Biologics, Kedrion, Pfizer, Roche/Genentech, Sanofi, Spark, Takeda, and UniQure and has ownership interests in Alnylam.
Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Miguel A. Escobar, MD, has disclosed that he has received consulting fees from CSL Behring, Genentech/Roche, Novo Nordisk, Sanofi, and Takeda.
Guy A. Young, MD

Professor of Pediatrics
Director,
Hemostasis and Thrombosis Center
Children's Hospital Los Angeles
University of Southern California Keck School of Medicine
Los Angeles, California

Guy A. Young, MD, has disclosed that he has received funds for research support from Genentech/Roche, Grifols, and Takeda and consulting fees from Biomarin, Genentech/Roche, Grifols, Novo Nordisk, Sanofi, Spark, Takeda, and UniQure.

Staff

Terrence Fagan

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.
Kristi Kay Orbaugh, RN, MSN, RNP, AOCN

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physicians
Indianapolis, Indiana

Kristi Orbaugh has no relevant conflicts of interest to report.
Jason Everly, PharmD

Director, Program Development and Educational Impact

Jason Everly has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

The live and online activities are intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with hemophilia A.

Goal

The goal of this activity is to educate physicians, pharmacists, nurses, and other healthcare professionals about hemophilia A without inhibitors.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education


Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-20-024-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 08, 2020, through December 07, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Hemophilia A Without Inhibitors: Personalizing Therapy With Factor VIII Prophylaxis: Webcast
  • CME
  • CE

Loading...
Review multidisciplinary perspectives on leveraging clotting factor concentrates for prophylaxis of hemophilia A with this Webcast from a hematology symposium.
Michael Callaghan, MD
Miguel A. Escobar, MD
Guy A. Young, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Registered Nurses: 1.0 Nursing contact hour
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: December 8, 2020 Expiration: December 7, 2021

Related Content

Dr. Corey S. Cutler shares his views on current and future graft-vs-host disease (GVHD) therapies in this commentary from Clinical Care Options (CCO)

Corey S. Cutler, MD, MPH, FRCPC Released: April 27, 2021

Interactive online tool providing expert management recommendations for β-thalassemia from Clinical Care Options (CCO)

Jeanne Boudreaux, MD person default Stephanie A. Fritch Lilla, MD Janet L. Kwiatkowski, MD, MSCE Sujit Sheth, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: April 22, 2021 Expired: April 21, 2022

On-demand Webcast updated with data from ASH 2020 with expert faculty discussing recent data on management of hemophilia A, presented by Clinical Care Options (CCO)

Miguel A. Escobar, MD
Program Director
Michael Callaghan, MD person default Rebecca Kruse-Jarres, MD, MPH
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: February 25, 2021 Expired: February 24, 2022

Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD: top picks of nonmalignant hematology studies from ASH 2020 as reported by CCO

Hanny Al-Samkari, MD Mark A. Schroeder, MD Sujit Sheth, MD Released: February 24, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Takeda Pharmaceuticals USA, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue